ClinicalTrials.gg

Program

C-CAR168

Its studies are mostly in Lupus Nephritis · Multiple Sclerosis, Chronic Progressive · Scleroderma, Systemic, led by AbelZeta.

Furthest: phase 2, since Mar 26, 20254 company-led studies, 3 open or runningNext primary completion: Dec 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbelZeta43 open or runningphase 2since Mar 26, 2025Mar 26, 2025Dec 2028phase 1 · NCT07854483

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 26, 2025First study: phase 2 study in Lupus NephritisFirst studyNCT06935474 · United States
  2. Jul 16, 2026Phase 2 study in Lupus NephritisNCT07729826 · 50 planned
  3. Sep 8, 2026Phase 2 study in Multiple SclerosisNCT07825389 · 119 planned · United States
  4. Sep 27, 2026Phase 1 study in Scleroderma, SystemicNCT07854483 · 12 planned · United States

Ahead

  1. Dec 2028Primary completion: phase 1 study in Scleroderma, SystemicNCT07854483
  2. Dec 31, 2028Primary completion: phase 2 study in Lupus NephritisNCT07729826
  3. Feb 2030Primary completion: phase 2 study in Multiple SclerosisNCT07825389

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07854483Scleroderma, Systemic · United States1Not yet recruitingDec 202812
NCT07825389Multiple Sclerosis · United States2Not yet recruitingFeb 2030119
NCT07729826Lupus Nephritis2Not yet recruitingDec 31, 202850
NCT06935474Lupus Nephritis · United States2WithdrawnMay 20290

How it is read

Names in the registry

  • “C-CAR168”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.